Krystal Biotech Inc (KRYS)
Healthcare
Biotechnology
341.10 $
-7.0%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Krystal Biotech Inc (KRYS)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 79.4% of the shares are freely tradable; institutional investors hold 99.4%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
99.4%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
11.0%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
79.4%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
19.5%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
30Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| FMR Inc | 14.84 | 4,373,987 | +0.6 | 03/31/2026 |
| BlackRock Inc | 13.37 | 3,940,456 | +0.1 | 03/31/2026 |
| venBio Select Advisor LLC | 9.80 | 2,888,888 | +0.0 | 03/31/2026 |
| Vanguard Portfolio Management, LLC | 4.94 | 1,456,727 | +0.0 | 03/31/2026 |
| State Street Corp | 4.46 | 1,314,434 | -2.1 | 03/31/2026 |
| Vanguard Capital Management, LLC | 3.95 | 1,165,324 | +0.0 | 03/31/2026 |
| Soleus Capital Management, L.P. | 3.91 | 1,153,087 | +22.5 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Fidelity Select Biotechnology | 6.11 | 1,802,622 | +0.0 | 06/30/2026 |
| Fidelity Growth Compy Commingled Pl S | 3.57 | 1,051,659 | +0.3 | 05/31/2026 |
| iShares Core S&P Mid-Cap ETF | 3.05 | 897,719 | +0.2 | 07/28/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.